Contineum Therapeutics, Class Stock Market Value
| CTNM Stock | 7.28 0.63 7.96% |
| Symbol | Contineum |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Contineum Therapeutics,. If investors know Contineum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Contineum Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Contineum Therapeutics, is measured differently than its book value, which is the value of Contineum that is recorded on the company's balance sheet. Investors also form their own opinion of Contineum Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Contineum Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Contineum Therapeutics,'s market value can be influenced by many factors that don't directly affect Contineum Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Contineum Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Contineum Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Contineum Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Contineum Therapeutics, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Contineum Therapeutics,'s stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Contineum Therapeutics,.
| 12/26/2024 |
| 03/26/2025 |
If you would invest 0.00 in Contineum Therapeutics, on December 26, 2024 and sell it all today you would earn a total of 0.00 from holding Contineum Therapeutics, Class or generate 0.0% return on investment in Contineum Therapeutics, over 90 days. Contineum Therapeutics, is related to or competes with Enel Chile, Southwest Gas, Old Dominion, Delek Logistics, Eastman Kodak, Yuexiu Transport, and Suburban Propane. More
Contineum Therapeutics, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Contineum Therapeutics,'s stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Contineum Therapeutics, Class upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.27) | |||
| Maximum Drawdown | 15.89 | |||
| Value At Risk | (6.58) | |||
| Potential Upside | 6.09 |
Contineum Therapeutics, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Contineum Therapeutics,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Contineum Therapeutics,'s standard deviation. In reality, there are many statistical measures that can use Contineum Therapeutics, historical prices to predict the future Contineum Therapeutics,'s volatility.| Risk Adjusted Performance | (0.22) | |||
| Jensen Alpha | (1.06) | |||
| Total Risk Alpha | (1.05) | |||
| Treynor Ratio | 4.11 |
Contineum Therapeutics, Backtested Returns
Contineum Therapeutics, secures Sharpe Ratio (or Efficiency) of -0.27, which signifies that the company had a -0.27 % return per unit of risk over the last 3 months. Contineum Therapeutics, Class exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Contineum Therapeutics,'s Risk Adjusted Performance of (0.22), mean deviation of 2.82, and Standard Deviation of 3.91 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.26, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Contineum Therapeutics, are expected to decrease at a much lower rate. During the bear market, Contineum Therapeutics, is likely to outperform the market. At this point, Contineum Therapeutics, has a negative expected return of -1.05%. Please make sure to confirm Contineum Therapeutics,'s potential upside, as well as the relationship between the rate of daily change and relative strength index , to decide if Contineum Therapeutics, performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.37 |
Below average predictability
Contineum Therapeutics, Class has below average predictability. Overlapping area represents the amount of predictability between Contineum Therapeutics, time series from 26th of December 2024 to 9th of February 2025 and 9th of February 2025 to 26th of March 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Contineum Therapeutics, price movement. The serial correlation of 0.37 indicates that just about 37.0% of current Contineum Therapeutics, price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.37 | |
| Spearman Rank Test | 0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 0.25 |
Contineum Therapeutics, lagged returns against current returns
Autocorrelation, which is Contineum Therapeutics, stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Contineum Therapeutics,'s stock expected returns. We can calculate the autocorrelation of Contineum Therapeutics, returns to help us make a trade decision. For example, suppose you find that Contineum Therapeutics, has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Contineum Therapeutics, regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Contineum Therapeutics, stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Contineum Therapeutics, stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Contineum Therapeutics, stock over time.
Current vs Lagged Prices |
| Timeline |
Contineum Therapeutics, Lagged Returns
When evaluating Contineum Therapeutics,'s market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Contineum Therapeutics, stock have on its future price. Contineum Therapeutics, autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Contineum Therapeutics, autocorrelation shows the relationship between Contineum Therapeutics, stock current value and its past values and can show if there is a momentum factor associated with investing in Contineum Therapeutics, Class.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Contineum Therapeutics, Correlation, Contineum Therapeutics, Volatility and Contineum Therapeutics, Alpha and Beta module to complement your research on Contineum Therapeutics,. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Contineum Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.